These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 19816648

  • 21. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, Walsh JS, Eastell R.
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [Abstract] [Full Text] [Related]

  • 22. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
    Lewiecki EM, Babbitt AM, Piziak VK, Ozturk ZE, Bone HG.
    Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
    [Abstract] [Full Text] [Related]

  • 23. Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years.
    McClung MR, Balske A, Burgio DE, Wenderoth D, Recker RR.
    Osteoporos Int; 2013 Jan; 24(1):301-10. PubMed ID: 23079690
    [Abstract] [Full Text] [Related]

  • 24. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
    Naylor KE, Jacques RM, Paggiosi M, Gossiel F, Peel NF, McCloskey EV, Walsh JS, Eastell R.
    Osteoporos Int; 2016 Jan; 27(1):21-31. PubMed ID: 25990354
    [Abstract] [Full Text] [Related]

  • 25. Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO).
    Iwamoto J, Okano H, Furuya T, Urano T, Hasegawa M, Hirabayashi H, Kumakubo T, Makita K.
    J Bone Miner Metab; 2016 Mar; 34(2):201-8. PubMed ID: 25794468
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.
    McClung MR, Miller PD, Brown JP, Zanchetta J, Bolognese MA, Benhamou CL, Balske A, Burgio DE, Sarley J, McCullough LK, Recker RR.
    Osteoporos Int; 2012 Jan; 23(1):267-76. PubMed ID: 21947137
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Early changes in 25-hydroxyvitamin D levels and bone markers after monthly risedronate with cholecalciferol in Korean patients with osteoporosis.
    Chung HY, Koo J, Kwon SK, Kang MI, Moon SH, Park JY, Shin CS, Yoon BK, Yoon HK, Chang JS, Chung YS, Park HM.
    Clin Interv Aging; 2013 Jan; 8():597-603. PubMed ID: 23761968
    [Abstract] [Full Text] [Related]

  • 30. Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy.
    Gold DT, Trinh H, Safi W.
    Curr Med Res Opin; 2009 Aug; 25(8):1831-9. PubMed ID: 19530982
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.
    Reginster JY, Felsenberg D, Cooper C, Stakkestad JA, Miller PD, Kendler DL, Adami S, McClung MR, Bolognese MA, Civitelli R, Dumont E, Bonvoisin B, Recker RR, Delmas PD.
    Osteoporos Int; 2006 Feb; 17(2):159-66. PubMed ID: 15959614
    [Abstract] [Full Text] [Related]

  • 33. Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate.
    Bonnick SL, Silverman S, Tanner SB, Martens M, Bachmann G, Kohles JD, Civitelli R.
    J Womens Health (Larchmt); 2009 Jul; 18(7):935-43. PubMed ID: 19563245
    [Abstract] [Full Text] [Related]

  • 34. A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data.
    McClung MR, Benhamou CL, Man Z, Tlustochowicz W, Zanchetta JR, Eusebio R, Balske AM, Matzkin E, Olszynski WP, Recker R, Delmas PD.
    Calcif Tissue Int; 2013 Jan; 92(1):59-67. PubMed ID: 23150144
    [Abstract] [Full Text] [Related]

  • 35. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
    Miller PD, Epstein S, Sedarati F, Reginster JY.
    Curr Med Res Opin; 2008 Jan; 24(1):207-13. PubMed ID: 18042311
    [Abstract] [Full Text] [Related]

  • 36. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
    Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C.
    J Bone Miner Res; 2005 Aug; 20(8):1315-22. PubMed ID: 16007327
    [Abstract] [Full Text] [Related]

  • 37. Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.
    Chapurlat RD.
    Treat Endocrinol; 2005 Aug; 4(2):115-25. PubMed ID: 15783248
    [Abstract] [Full Text] [Related]

  • 38. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
    Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE, Fosamax Actonel Comparison Trial Investigators.
    J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
    [Abstract] [Full Text] [Related]

  • 39. Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
    Palacios S, Agodoa I, Bonnick S, Van den Bergh JP, Ferreira I, Ho PR, Brown JP.
    J Clin Endocrinol Metab; 2015 Mar; 100(3):E487-92. PubMed ID: 25514106
    [Abstract] [Full Text] [Related]

  • 40. Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis.
    Moro-Alvarez MJ, Díaz-Curiel M.
    Clin Interv Aging; 2008 Mar; 3(2):227-32. PubMed ID: 18686745
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.